Mac-2 binding protein glycosylation isomer as a novel predictor of early recurrence after resection for hepatocellular carcinoma.

IF 1.7 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2024-06-28 DOI:10.1007/s00595-024-02885-z

Kyohei Yugawa, Takashi Maeda, Keiji Tsuji, Mototsugu Shimokawa, Akihiro Sakai, Shohei Yamaguchi, Kozo Konishi, Kenkichi Hashimoto

{"title":"Mac-2 binding protein glycosylation isomer as a novel predictor of early recurrence after resection for hepatocellular carcinoma.","authors":"Kyohei Yugawa, Takashi Maeda, Keiji Tsuji, Mototsugu Shimokawa, Akihiro Sakai, Shohei Yamaguchi, Kozo Konishi, Kenkichi Hashimoto","doi":"10.1007/s00595-024-02885-z","DOIUrl":null,"url":null,"abstract":"Purpose: Hepatocellular carcinoma (HCC) frequently recurs after radical resection, resulting in a poor prognosis. This study assessed the prognostic value of Mac-2 binding protein glycosylation isomer (M2BPGi) for early recurrence (ER) in patients with HCC.Methods: Patients who underwent radical resection for HCC between 2015 and 2021. HCC recurrence within one year after curative resection was defined as ER.Results: The 150 patients were divided into two groups: non-ER (116, 77.3%) and ER (34, 22.7%). The ER group had a lower overall survival rate (p < 0.0001) and significantly higher levels of M2BPGi (1.06 vs. 2.74 COI, p < 0.0001) than the non-ER group. High M2BPGi levels (odds ratio [OR] 1.78, 95% confidence interval [CI] 1.31-2.41, p < 0.0001) and a large tumor size (OR 1.31, 95% CI, 1.05-1.63; p = 0.0184) were identified as independent predictors of ER. M2BPGi was the best predictor of ER according to a receiver operating characteristic (ROC) analysis (area under the ROC curve 0.82, p < 0.0001).Conclusions: M2BPGi can predict ER after surgery and is useful for risk stratification in patients with HCC.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-024-02885-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Hepatocellular carcinoma (HCC) frequently recurs after radical resection, resulting in a poor prognosis. This study assessed the prognostic value of Mac-2 binding protein glycosylation isomer (M2BPGi) for early recurrence (ER) in patients with HCC.

Methods: Patients who underwent radical resection for HCC between 2015 and 2021. HCC recurrence within one year after curative resection was defined as ER.

Results: The 150 patients were divided into two groups: non-ER (116, 77.3%) and ER (34, 22.7%). The ER group had a lower overall survival rate (p < 0.0001) and significantly higher levels of M2BPGi (1.06 vs. 2.74 COI, p < 0.0001) than the non-ER group. High M2BPGi levels (odds ratio [OR] 1.78, 95% confidence interval [CI] 1.31-2.41, p < 0.0001) and a large tumor size (OR 1.31, 95% CI, 1.05-1.63; p = 0.0184) were identified as independent predictors of ER. M2BPGi was the best predictor of ER according to a receiver operating characteristic (ROC) analysis (area under the ROC curve 0.82, p < 0.0001).

Conclusions: M2BPGi can predict ER after surgery and is useful for risk stratification in patients with HCC.

Abstract Image

查看原文本刊更多论文

Mac-2结合蛋白糖基化异构体是预测肝细胞癌切除术后早期复发的新指标。

目的：肝细胞癌（HCC）根治性切除术后经常复发，导致预后不良。本研究评估了Mac-2结合蛋白糖基化异构体（M2BPGi）对HCC患者早期复发（ER）的预后价值：方法：2015年至2021年间接受HCC根治性切除术的患者。方法：2015 年至 2021 年期间接受 HCC 根治性切除术的患者，将治愈性切除术后一年内的 HCC 复发定义为 ER：150例患者分为两组：非ER组（116例，77.3%）和ER组（34例，22.7%）。ER组的总生存率较低（P 结论：M2BPGi可预测ER：M2BPGi可预测术后ER，有助于对HCC患者进行风险分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.